Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Other Accumulated Expenses (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Other Accumulated Expenses readings, the most recent being $394000.0 for Q4 2024.

  • On a quarterly basis, Other Accumulated Expenses rose 39.22% to $394000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $394000.0, a 39.22% increase, with the full-year FY2024 number at $394000.0, up 39.22% from a year prior.
  • Other Accumulated Expenses hit $394000.0 in Q4 2024 for Unicycive Therapeutics, up from $29000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $522000.0 in Q4 2022 to a low of $29000.0 in Q3 2024.
  • Median Other Accumulated Expenses over the past 4 years was $250000.0 (2024), compared with a mean of $266555.6.
  • Biggest five-year swings in Other Accumulated Expenses: surged 243.42% in 2022 and later plummeted 94.21% in 2024.
  • Unicycive Therapeutics' Other Accumulated Expenses stood at $152000.0 in 2021, then surged by 243.42% to $522000.0 in 2022, then tumbled by 45.79% to $283000.0 in 2023, then surged by 39.22% to $394000.0 in 2024.
  • The last three reported values for Other Accumulated Expenses were $394000.0 (Q4 2024), $29000.0 (Q3 2024), and $121000.0 (Q2 2024) per Business Quant data.